Table 1.

Early results of the clinical studies with imatinib treatment in metastatic GIST patients

Study group (Ref.)Study designImatinib dose (mg)Total patientsOverall PR + SD (%)2-y Progression-free survivalFollow-up period (mo)
EORTC (16)Phase I400-1,0003551 + 31NAMinimum: 9
US-Finland (17)Phase II randomized400 versus 60014754 + 28NAMinimum: 9
EORTC (18)Phase II4002771* + 18NAMinimum: 12
NCI (19) (Intergroup S0033)Phase III randomized400 versus 80074648* + 2650% versus 53% (P > 0.05)Median: 25
EORTC, ISG, AGITG (20)Phase III randomized400 versus 80094651* + 3350% versus 56% (P = 0.026)Median: 25
  • Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; NCI, National Cancer Institute; ISG, Italian Sarcoma Group; AGITG, Australasian Gastro-Intestinal Trials Group; PR, partial response; SD, stable disease; NA, not available.

  • * Including 3% to 5% of patients achieving complete remission